Skip to main content

Advertisement

Table 2 Summary of adverse events

From: S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial

Adverse events SCCR (n = 20) CCR (n = 20)
G3/4 (≥G3) (%) G3/4 (≥G3) (%)
Haematolgic
  Leukopenia 4/1 (25.0%) 3/1 (20.0%)
  Thrombocytopenia 4/0 (20.0%) 3/1 (20.0%)
  Neutropenia 4/0 (20.0%) 3/0 (15.0%)
  Febrile neutropenia 3/0 (15.0%) 3/0 (15.0%)
  Anaemia 3/0 (15.0%) 2/0 (10.0%)
Non-haematolgic
  Anorexia 3/0 (15.0%) 2/0 (10.0%)
  Nausea 1/1 (10.0%) 2/0 (10.0%)
  Constipation 2/0 (10.0%) 2/0 (10.0%)
  Oesophagitis 2/0 (10.0%) 1/0 (5.0%)
  Fatigue 1/0 (5.0%) 2/0 (10.0%)
  ALT, AST 1/0 (5.0%) 0/0 (0%)
  Pneumonitis 1/0 (5.0%) 0/0 (0%)
  Diarrhoea 0/0 (0%) 1/0 (5.0%)